Further, ideal therapeutic vectors (e.g., adeno-associated virus) carrying PRDM1 gene are currently needed to be developed to evaluate their safety and potential to serve as vital anti-tumor drugs, for synergistically increasing the efficacy of PD-(L)1-based therapies. The gene discussed is CD274; the disease is neoplasm.